We bring you our round-up of the latest legal and commercial issues for life sciences businesses.
As we approach the end of the Brexit transition period, we cover two key issues for businesses in the sector: mutual recognition agreements and changes to the immigration regime. We also give a legal overview of two key industry terms: marketing authorisation and medical devices, and look at the new arbitration rules recently introduced by the LCIA.
A link to the web version of this email update is available here. If you would like to receive these updates via email, please subscribe.
Charlotte Tillett
Gustaf Duhs